McMaster University

Ketone drinks: do they really improve sports performance?

Retrieved on: 
Thursday, July 6, 2023
Taste, Exercise, Tissue, Diet, Magic, Fats, Glucose, Weight loss, Ketone bodies, Brain, Research, Attention, Athlete, McMaster University, Sodium bicarbonate, Blood, Carbohydrate, Ketone, Sport, KU Leuven, Dietary supplement, Animal feed, Asterix

But do they really improve performance?

Key Points: 
  • But do they really improve performance?
  • Ketone bodies can also be used in other tissues, such as muscle, and could eventually be used as fuel during exercise.
  • Initially, most ketone supplements caused gastrointestinal issues and did not sufficiently increase ketone body availability.
  • A newer ketone monoester (ketone body bound to a compound called monoester) drink was shown not to cause gastrointestinal discomfort and to sufficiently increase ketone body concentrations in the blood.

Government strengthens Canada's leadership role in medical isotope production

Retrieved on: 
Tuesday, June 27, 2023
SON, Canadian Nuclear Laboratories Research Facilities, Commercialization, Saugeen Ojibway Nation Territory, The Honourable, Partnership, Medicine, COVID-19, Cancer, Isotope, Research, Radiopharmaceutical, Google Images, Government, Parliament, Nuclear medicine, Bruce Power, Acceleration, Hope, McMaster University, Patient, Investment, Public security, Health, First Nations, Government of Canada, Growth, Diagnosis, Federation, Ecosystem, Safety, Void coefficient, Medical imaging, Pharmaceutical industry, Palladium, Medical device, Science

Canada has played a key leadership role in the development and use of medical isotopes for over 70 years, positioning the country as a global leader in the production and supply of medical isotopes.

Key Points: 
  • Canada has played a key leadership role in the development and use of medical isotopes for over 70 years, positioning the country as a global leader in the production and supply of medical isotopes.
  • This funding responds to the Canadian Nuclear Isotope Council's report, Isotopes for Hope: Canadian Leadership Needed Now More Than Ever, calling on the federal government to invest in the growth of Canada's medical isotope ecosystem.
  • The Canadian Medical Isotope Ecosystem will play a crucial role in the development and distribution of medical isotopes and radiopharmaceuticals across the country.
  • The new Canadian Medical Isotope Ecosystem brings together government, industry and academia to work collaboratively to build Canadian medical isotope capabilities and ensure Canada remains a leader in this high-growth sector."

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
Michael G. DeGroote School of Medicine, Drug development, Therapy, Research, CCCC, Bladder cancer, Genentech, Chemistry, National Cancer Institute, Queen Elizabeth, McMaster University, Patient, Queen Elizabeth II Health Sciences Centre, Astellas Pharma, Sanofi, FDA, Breast cancer, Disease, Pharmaceutical industry, Dalhousie

WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.

Key Points: 
  • Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials.
  • At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.
  • “We look forward to leveraging Len’s track record of advancing novel oncology therapeutics to patients, deep strategic and operational experience in clinical development and organizational leadership capabilities,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
  • Prior to Pionyr, he was executive vice president and chief medical officer at ORIC Pharmaceuticals, leading their first product candidate into human trials.

Oasis Names Thomas Atkinson to Advisory Council

Retrieved on: 
Monday, June 12, 2023
Finance, Banking, Professional Services, Legal, Asset Management, South Carolina Law Enforcement Division, IPO, Legislation, University, Justice, Public policy, Ontario Securities Commission, Toronto Stock Exchange, Ontario Court of Justice, SFC, Oasis, Independent Commission Against Corruption (Hong Kong), China Securities Regulatory Commission, Claims management company, Person, Master's degree, Advisory Council, Independent Commission Against Corruption, McMaster University, Securities and Futures Commission, Ethics, CSRC, Structure of the Hong Kong Police Force, OSC, Property management

Oasis Management Company Ltd. (“Oasis”) is pleased to announce that Thomas Atkinson has joined its Advisory Council.

Key Points: 
  • Oasis Management Company Ltd. (“Oasis”) is pleased to announce that Thomas Atkinson has joined its Advisory Council.
  • From 1996 to 2001 he held progressively senior positions with the Toronto Stock Exchange, including Vice President of Regulation Services.
  • Mr. Atkinson is a frequent speaker and lecturer on topics related to securities regulation, compliance, ethics, management, leadership, and other related topics.
  • “Tom is an experienced leader in global capital markets and international securities market regulation,” said Seth Fischer, Founder and Chief Investment Officer at Oasis.

More than 3,500 Riders Cycle Over 200km to Raise Critical Funds for Cancer Research at The Princess Margaret

Retrieved on: 
Saturday, June 10, 2023
Niagara Falls Transit, Niagara Falls, Event, Princess Margaret Cancer Centre, The Ride to Conquer Cancer, Exhibition Place, Kenosha/Racine Lead-Free Communities Partnership, Princess Margaret, Countess of Snowdon, Rider, Cancer, Statistics, Research, McMaster University, Corporation, Exhibition, Ride, Conquer, Leukemia, Health, Death, Chair, Ridesharing, Pharmaceutical industry, Amusement park

The Princess Margaret unites Riders from across Canada and around the world for the 200km+ Ride to Conquer Cancer on June 10 and 11.

Key Points: 
  • The Princess Margaret unites Riders from across Canada and around the world for the 200km+ Ride to Conquer Cancer on June 10 and 11.
  • TORONTO, June 10, 2023 /CNW/ - More than 3,500 Riders left Exhibition Place in Toronto for The Princess Margaret Cancer Foundation's 16th annual Ride to Conquer Cancer, Canada's largest athletic fundraiser.
  • So far, this year's event has raised $17.3 million for life-saving cancer research and care at Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world.
  • "Cancer is the leading cause of death in Canada – two in five Canadians will be diagnosed with cancer in their lifetime.

Hammond Power Solutions Announces Adrian Thomas as Chief Executive Officer

Retrieved on: 
Tuesday, June 6, 2023
Executive, General Electric, GE, Carbon, HPS, TMEIC, McMaster University, Schneider Electric, TSX, Growth, European Chamber of Commerce in Korea, Family, The Garage at Northwestern University, Commerce, Kellogg School of Management, Management, Industrial design, Electric motor, European

GUELPH, Ontario, June 06, 2023 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) today announced the appointment of Adrian Thomas as the Company's next Chief Executive Officer, replacing Bill Hammond who will assume the position of Executive Chairman after 22 years as the CEO.

Key Points: 
  • GUELPH, Ontario, June 06, 2023 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) today announced the appointment of Adrian Thomas as the Company's next Chief Executive Officer, replacing Bill Hammond who will assume the position of Executive Chairman after 22 years as the CEO.
  • Mr. Thomas will also be appointed to HPS’ Board of Directors.
  • "Adrian is a highly capable and seasoned leader with over two decades of experience across the electrical industry and has successfully led teams launching technologies globally,” said Grant Robinson, Lead Director of HPS.
  • Adrian holds a degree in electrical engineering from McMaster University and a post-graduate certificate in finance for executives from Northwestern University's Kellogg School of Management.

Cubic and McMaster Partnership Recognized in 7th Edition of the UITP Awards

Retrieved on: 
Monday, June 5, 2023
Public Transport, Apps, Applications, Other Transport, Mobile, Wireless, Technology, Trucking, Rail, Transport, Software, Hardware, Integrated Strategies, Asian Young Researchers Conference on Computational and Omics Biology, McMaster Innovation Park, Partnership, UI, Cubic Corporation, Speech, Disability, MARC, Research, McMaster, Creativity, CTS, McMaster University, Engineering, UITP, Artificial intelligence, Virtual reality, Intelligent transportation system, City, Environment, Medical device, Video game, Cubic

Cubic Transportation Systems (CTS), part of Cubic Corporation , and McMaster University today announced that Dr. Hanna Haponenko, postdoc at McMaster Automotive Resource Centre (MARC) , has been recognized with the UITP Young Researcher Award.

Key Points: 
  • Cubic Transportation Systems (CTS), part of Cubic Corporation , and McMaster University today announced that Dr. Hanna Haponenko, postdoc at McMaster Automotive Resource Centre (MARC) , has been recognized with the UITP Young Researcher Award.
  • The honor celebrates her work and contributions towards Mobility Cube — a collaborative program between Cubic and McMaster University in Hamilton, Ontario, Canada, focusing on Artificial Intelligence and Smart Mobility.
  • The award was announced at the UITP Global Public Transport Summit held June 4-7, 2023 in Barcelona.
  • Her dedication to advancing accessibility in transportation has earned her recognition, including the UITP Young Researcher Award.

Listen: Trans scholar and activist explains why trans rights are under attack

Retrieved on: 
Friday, June 2, 2023
People, MAGA, Transgender studies, The Conversation, Archive, Queer, Violence, All Power to the People, Toronto Star, Spotify, History, Black, Government, Pulse, Syrus Marcus Ware, Student, Journal, Google Podcasts, McMaster University, Refugee, School, Supreme court, Sport, Extra, Woman, CPAC, Legislation, Drug, Interior design, Mail order, Computer data storage, Pride, Facebook

Some of the legislation denies gender-affirming care to youth – and criminalizes those health-care providers that attempt to do so.

Key Points: 
  • Some of the legislation denies gender-affirming care to youth – and criminalizes those health-care providers that attempt to do so.
  • Other bills block trans students from participating in sports and still others have banned books with trans content.
  • They all aim to make being trans harder in an already hostile society and they are being spearheaded by the far-right.
  • The enforcement of a gender binary likely has much to do with the preservation of white power.

Unleashing the Power of Virtual Reality: McMaster University & Virtualware’s IMRSV@Mac VR Lab!

Retrieved on: 
Wednesday, May 31, 2023
Faculty, Enterprise, McMaster Innovation Park, Partnership, Engineering, Research, Transport, VR, Canada Research Chair, EPA, Student, MIP, McMaster University, McMaster Faculty of Engineering, Vehicle registration plates of Nepal, Video game, Management

HAMILTON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- The Faculty of Engineering at McMaster University, in partnership with the VR company Virtualware (EPA: MLVIR), officially announces the grand opening of the New VR Lab called IMRSV@MAC powered by VIROO®.

Key Points: 
  • HAMILTON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- The Faculty of Engineering at McMaster University, in partnership with the VR company Virtualware (EPA: MLVIR), officially announces the grand opening of the New VR Lab called IMRSV@MAC powered by VIROO®.
  • IMRSV@MAC is poised to become a leading destination for technology enthusiasts, aiming to accelerate the adoption of VR through collaborative efforts between academia and industry.
  • The VR Lab will serve as a catalyst for the development of future-proof skills in research, career advancement, and professional growth across all sectors.
  • The four-year partnership between McMaster University and Virtualware will leverage each organization’s strengths to accelerate the adoption of VR in academic and enterprise sectors.

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Retrieved on: 
Tuesday, May 30, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Inc., Factor IX, Bleeding, Factor VIII, PFE, ABR, Haemophilia, Pfizer, FIX, Assistant, McMaster University, Patient, Data, TFPI, Purpura, NYSE, Disease, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial ( NCT03938792 ) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.
  • “These results support the potential for marstacimab to become the first once-weekly non-factor treatment for people with hemophilia B and a treatment option that helps address the diverse needs of patients with hemophilia A or B without inhibitors.
  • The safety profile for marstacimab was consistent with Phase 1/2 results and treatment was generally well-tolerated.
  • Pfizer currently has three Phase 3 programs investigating novel treatment options for people living with hemophilia.